GLPwatch
Efficacy and safety of once-weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index.
J Diabetes · 2021
Last updated 2026-05-28In a study of Chinese adults with type 2 diabetes and a BMI below 25, the drug dulaglutide improved blood sugar control, led to a small reduction in body weight, and had a low risk of causing dangerously low blood sugar. The results suggest dulaglutide is both effective and safe for these patients, regardless of their BMI.
AI summary of the abstract below.
| Journal | J Diabetes, 2021 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.12 |
| NIH percentile | 8 |
| Molecules | dulaglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
Highlights In Chinese patients with type 2 diabetes (T2D) and body mass index (BMI) <25 kg/m , dulaglutide demonstrated great improvements in glycemic control with mild body weight reduction and low hypoglycemia risk. The results indicate that dulaglutide is effective and safe in patients with T2D and lower BMI; therefore, BMI should not be a consideration when dulaglutide is prescribed to Chinese patients with T2D.
Verbatim abstract via PubMed 33325105 ↗
Related research
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
- Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).